Having trouble accessing articles? Reset your cache.

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

Efficacy for Btk, FLT3 inhibitor in blood cancers
In a pair of posters at the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc. (NASDAQ:APTO; TSX:APS) and University of Texas MD Anderson Cancer Center researchers reported preclinical proof of concept for CG-806 in chronic lymphocytic leukemia

Read the full 474 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE